Syntax

Venture Round
syntax-bio.com Biotech & Healthcare
Total Funding $14.4M
Latest Round $14.4M Venture Round
Last Announced Jun 22, 2026
Investors Undisclosed
Decision Makers 4 Verified

About Syntax

Syntax Bio is a synthetic biology company programming the next generation of stem cell-derived therapies and organoids.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Venture Round
Global Headquarters Undisclosed
Tracked Since Sep 29, 2026

Web & Domain Identity

Official Website syntax-bio.com
Domain Registered Date Jan 2, 2024

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Raised $14,400,000 · Venture Round

    fundraisingfox.com

  2. Milestone

    Website domain registered

    syntax-bio.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Syntax.

Funding History

1 Round
Venture Round · Jun 22, 2026

Founders & Leadership

4

Brad Merrill

Co-Founder, Head of Innovation

Work email & phone locked Unlock →

Doug Doerfler

Founder, CEO, Board Advisor

Work email & phone locked Unlock →

Niko Balanis

Co-Founder, Chief Technology Officer

Work email & phone locked Unlock →

Ryan Clarke

Co-Founder, Chief Scientific Officer

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts